Subarachnoid hemorrhage (SAH) is a life-threatening condition characterized by bleeding in the space between the brain and its surrounding membranes. It accounts for 3% to 5% of the global cerebrovascular disease burden, affecting around 500,000 individuals annually. The disease often results in significant neurological impairment or death. There is a high unmet clinical need for more effective therapies, as current treatment options, such as surgical intervention and blood pressure management, are limited in addressing long-term outcomes. The growing focus on advanced subarachnoid hemorrhage drugs is expected to support pipeline growth and improve patient prognosis in the coming years.
The Subarachnoid Hemorrhage Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into subarachnoid hemorrhage therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for subarachnoid hemorrhage. The subarachnoid hemorrhage report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The subarachnoid hemorrhage pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with subarachnoid hemorrhage treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to subarachnoid hemorrhage.
Subarachnoid hemorrhage is a life-threatening condition in which bleeding occurs in the space between the brain and the surrounding membrane. It is commonly caused by the rupture of an aneurysm, trauma, or arteriovenous malformations. This hemorrhage leads to increased intracranial pressure and potential brain damage, often resulting in a sudden severe headache, nausea, and loss of consciousness.
Subarachnoid hemorrhage treatments focus on stabilizing the patient, preventing rebleeding, and managing complications. Surgical interventions include clipping or coiling aneurysms. Additionally, blood pressure control, vasospasm management, and neuroprotective therapies are crucial. Antifibrinolytics may be used to prevent rebleeding, while rehabilitation therapies are often necessary for recovery.
Subarachnoid hemorrhage is a critical cerebrovascular condition, comprising 3% to 5% of all cerebrovascular diseases, with an estimated 500,000 new cases globally each year. The incidence in the United Kingdom is approximately 8 per 100,000 individuals, with women being more likely to be affected. In the United States, it occurs in 10 to 14 individuals per 100,000 individuals annually, while a global meta-analysis reports an incidence of 7.9 per 100,000, higher in Asian populations.
This section of the report covers the analysis of subarachnoid hemorrhage drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total subarachnoid hemorrhage clinical trials.
The drug molecule categories covered under the subarachnoid hemorrhage pipeline analysis include small molecules, biologics, gene therapies, peptides, and cell-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for subarachnoid hemorrhage.
The EMR report for the subarachnoid hemorrhage report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in subarachnoid hemorrhage clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for subarachnoid hemorrhage. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of subarachnoid hemorrhage drug candidates.
The clinical trial, sponsored by Aaron Cook from the University of Kentucky, aims to evaluate the CNS penetration of telavancin in patients with subarachnoid hemorrhage. This Phase 4 study will examine the drug's cerebrospinal fluid (CSF) concentrations in critically ill patients with external ventricular drains (EVDs). The study is expected to be completed by January 2026, with an estimated 20 participants.
The Phase II trial, sponsored by Assistance Publique - Hôpitaux de Paris, is evaluating Levosimendan's impact on delayed cerebral ischemia and cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage. With around 30 participants, the trial is expected to conclude by January 2025.
Montefiore Medical Center is sponsoring a Phase 1 trial investigating prophylactic antibiotics with antibiotic-impregnated external ventricular drains (EVDs). The study aims to assess ventriculostomy-related infections in subarachnoid hemorrhage and related conditions. It compares 24-hour antibiotic use versus prolonged use. It is expected to enroll about 84 participants, with completion anticipated by June 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Subarachnoid Hemorrhage Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for subarachnoid hemorrhage. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within subarachnoid hemorrhage pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share